Search results for " thromboembolism"

showing 10 items of 158 documents

Prevalence of renal failure and use of antithrombotic prophylaxis among medical inpatients at increased risk of venous thromboembolic events.

2007

Abstract Background Evidence-based guidelines recommend the use of antithrombotic prophylaxis in medical patients at risk of venous thromboembolism (VTE). Low molecular weight heparins (LMWHs) are usually preferred to unfractionated heparin. However, when prophylactic doses of LMWH are administered, patients with renal failure (RF) are exposed to the risk of excessive accumulation, and thus to an increased risk of bleeding. We aimed to assess the prevalence of RF among medical inpatients at increased risk of VTE and the use and dosage of antithrombotic prophylaxis in these patients. Methods In a cross sectional study carried out at three different hospitals, information on all medical inpat…

Malemedicine.medical_specialtyCross-sectional studyAntithrombotic treatmentFibrinolytic AgentsInternal medicineAntithromboticmedicinePrevalenceHumansProspective StudiesRenal InsufficiencyMedical prescriptionIntensive care medicineAgedbusiness.industryHematologyHeparinVenous ThromboembolismHeparin Low-Molecular-WeightMiddle AgedIncreased riskCross-Sectional StudiesFemalebusinessVenous thromboembolismmedicine.drug
researchProduct

High incidence of venous thrombosis after surgery for abdominal aortic aneurysm

2009

Objective The incidence of venous thromboembolism (VT) after aortic abdominal aneurysm (AAA) surgery is imprecisely reported. On one hand, thromboprophylaxis has improved, on the other hand, AAA patients have become older and/or present worse comorbidities. Herein, we prospectively analyzed the incidence of VT in a continuous series of patients operated on for AAA repair and looked for predictive factors. Materials and Methods Between January 1, 2005, and December, 31, 2006, 193 consecutive patients (177 men and 16 women), mean age 73 (range, 47-93) underwent elective AAA repair, 137 open (71%) and 56 endovascular (29%), in our institution. Thromboprophylaxis consisted of thigh-length compr…

Malemedicine.medical_specialtyDeep veinDrug Administration ScheduleAortic aneurysmRisk FactorsmedicineHumansProspective StudiesEnoxaparinEarly AmbulationAgedUltrasonographyAged 80 and overVenous Thrombosisbusiness.industryHeparinIncidenceAnticoagulantsTransfusion ReactionPerioperativeVenous ThromboembolismMiddle Agedmedicine.diseaseThrombosisAbdominal aortic aneurysmSurgeryVenous thrombosismedicine.anatomical_structureTreatment OutcomeAnesthesiaSurgeryFemaleFresh frozen plasmaCardiology and Cardiovascular MedicinebusinessVascular Surgical ProceduresStockings CompressionAbdominal surgeryAortic Aneurysm AbdominalJournal of Vascular Surgery
researchProduct

Survival and recurrent venous thromboembolism in patients with first proximal or isolated distal deep vein thrombosis and no pulmonary embolism

2017

Essentials The long-term risk of recurrence and death after distal deep vein thrombosis (DVT) is uncertain. We included subjects with first proximal or isolated distal DVT (IDDVT) and no pulmonary embolism. The risk of symptomatic and asymptomatic recurrence is lower after IDDVT (vs. proximal). IDDVT may be associated with a lower long-term risk of death, especially after unprovoked DVT. SummaryBackground A few studies have focused on the risk of recurrence after first acute isolated distal deep vein thrombosis (IDDVT) compared with proximal DVT (PDVT), whereas the incremental risk of death has never been explored beyond the first 3 years after acute event. Methods Our single-center cohort …

Malemedicine.medical_specialtyDeep veinKaplan-Meier Estimate030204 cardiovascular system & hematologyLower riskGastroenterologyAsymptomaticVeinsanticoagulation; death; distal deep vein thrombosis; pulmonary embolism; venous thromboembolism; Hematology03 medical and health sciences0302 clinical medicineRecurrenceRisk FactorsdeathInternal medicinemedicineHumans030212 general & internal medicineanticoagulationAgedVenous Thrombosisbusiness.industryMortality rateHazard ratioVenous ThromboembolismHematologyMiddle Agedmedicine.diseaseThrombosisSurgeryPulmonary embolismVenous thrombosisTreatment Outcomemedicine.anatomical_structureFemaledistal deep vein thrombosismedicine.symptomPulmonary EmbolismbusinessFollow-Up StudiesJournal of Thrombosis and Haemostasis
researchProduct

Measuring functional limitations after venous thromboembolism: A call to action.

2019

The main objectives of therapeutic trials in venous thromboembolism (VTE) are to prevent recurrent VTE, major bleeding and death. While these outcomes are indeed highly relevant, they are also rare and do not fully capture the overall functional outcome of VTE patients. Importantly, functional limitations after VTE are prevalent after both deep vein thrombosis and pulmonary embolism occurring in up to 50% of patients. These post-VTE syndromes are associated with a decreased quality of life, higher risk of depressive disorders, unemployment and increased utilization of healthcare resources. Because of the major impact of functional limitations on individual patients and society as a whole, d…

Malemedicine.medical_specialtyDeep veinMann Whitney U test030204 cardiovascular system & hematologyValue-based healthcare03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Postthrombotic syndromeRisk FactorsDeep vein thrombosisHealth carepulmonary hypertensionmedicineHumanscardiovascular diseasesIntensive care medicineVenous Thrombosisbusiness.industryPulmonary embolismActivities of daily livingAnticoagulantsHematologyVenous Thromboembolismmedicine.diseaseequipment and suppliesClassificationThrombosisCall to actionPulmonary embolismClinical trialmedicine.anatomical_structure030220 oncology & carcinogenesisScale (social sciences)FemalebusinessThrombosis research
researchProduct

Impact of Systemic Atherosclerosis on Clinical Characteristics and Short-Term Outcomes in Patients with Deep Venous Thrombosis or Thrombophlebitis

2020

Venous thromboembolism (VTE) and atherosclerosis are accompanied by substantial cardiovascular mortality; links between both disease entities were reported. We aimed to investigate the impact of systemic atherosclerosis on adverse outcomes in patients with deep venous thrombosis or thrombophlebitis (DVT) and to identify differences in DVT patients with and without systemic atherosclerosis.The German nationwide inpatient sample was used for this analysis. Patients admitted for DVT were included in this study and stratified by systemic atherosclerosis (composite of coronary artery disease, myocardial infarction, ischemic stroke, and/or atherosclerotic arterial diseases). We compared DVT patie…

Malemedicine.medical_specialtyDiseaseThrombophlebitisCoronary artery diseaseRisk FactorsInternal medicinemedicineHumanscardiovascular diseasesMyocardial infarctionVenous Thrombosisbusiness.industryVenous ThromboembolismGeneral MedicineThrombophlebitisAtherosclerosismedicine.diseasePulmonary embolismVenous thrombosisConcomitantHeart failureCardiologyFemalePulmonary EmbolismbusinessThe American Journal of the Medical Sciences
researchProduct

Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baselin…

2021

Abstract Introduction Sex and the presence of specific provoking risk factors, along with age, influence the presentation and prognosis of venous thromboembolism (VTE). We investigated the presentation, course and quality of life in women and men with acute VTE classified according to their VTE provoking factors. Methods PREFER in VTE is an international, non-interventional registry of patients with a first episode of acute symptomatic VTE. Baseline provoking factors were classified as follows: major transient, minor transient, active cancer, and none identifiable. The primary outcome was recurrent VTE. Quality of life and treatment satisfaction were secondary outcomes. Results Of 3,455 pat…

Malemedicine.medical_specialtyEpidemiology610 Medicine & health030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineQuality of lifeRecurrenceInternal medicineDeep vein thrombosisEpidemiologyInternal MedicineMedicineHumanscardiovascular diseases030212 general & internal medicineFirst episodeSex Characteristicsbusiness.industry10031 Clinic for AngiologyAbsolute risk reductionCancerAnticoagulantsVenous Thromboembolismequipment and suppliesmedicine.diseaseSex specificNeoplasm RecurrenceRisk factorsLocal2724 Internal MedicineQuality of LifeSexFemalePresentation (obstetrics)Neoplasm Recurrence LocalbusinessVenous thromboembolism
researchProduct

A prospective cohort study to identify and evaluate endotypes of venous thromboembolism: Rationale and design of the Genotyping and Molecular Phenoty…

2019

Abstract Several clinical, genetic and acquired risk factors for venous thromboembolism (VTE) have been identified. However, the molecular pathophysiology and mechanisms of disease progression remain poorly understood. This is reflected by uncertainties regarding the primary and secondary prevention of VTE and the optimal duration of antithrombotic therapy. A growing body of literature points to clinically relevant differences between VTE phenotypes (e.g. deep vein thrombosis (DVT) versus pulmonary embolism (PE), unprovoked versus provoked VTE). Extensive links to cardiovascular, inflammatory and immune-related morbidities are testament to the complexity of the disease. The GMP-VTE project …

Malemedicine.medical_specialtyGenotypeDeep veinDisease030204 cardiovascular system & hematologyCohort Studies03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineAntithromboticmedicineHumansProspective Studiescardiovascular diseasesProspective cohort studybusiness.industryVenous ThromboembolismHematologyMiddle Agedequipment and suppliesmedicine.diseaseThrombosisPulmonary embolismPhenotypemedicine.anatomical_structure030220 oncology & carcinogenesisConcomitantFemalebusinessCohort studyThrombosis Research
researchProduct

More than one in two venous thromboembolism treated in French hospitals occurs during the hospital stays

2016

Objective The objective was to describe the prevalence of venous thromboembolism, pulmonary embolism, and deep vein thrombosis among hospitalized patients and the percentages of those occurring during the hospital stays. Methods French DRG gave now the opportunity to investigate the frequency of venous thromboembolism occurring during the hospital stay. Statistics are issued from the national PMSI MCO databases encoded using the CIM10. Since 2010–2011 it is possible to differentiate the reason for hospital admission from the pathologies which secondly occurred. Any stay with the ICD-10 codes selected was considered as a hospital-occurred thrombosis unless it was the principal diagnosis of t…

Malemedicine.medical_specialtyHospitalized patientsEpidemiologyDeep vein030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineEpidemiologymedicineHumans030212 general & internal medicineIntensive care medicineCancerbusiness.industryHospital-Acquired Pulmonary EmbolismGeneral MedicineVenous ThromboembolismLength of Stay[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.diseaseThrombosisPulmonary embolismmedicine.anatomical_structureEmergency medicinePulmonary-EmbolismFemaleFranceCardiology and Cardiovascular MedicinebusinessPulmonary EmbolismVenous thromboembolism
researchProduct

Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2) : a multinational, multicentre, single-ar…

2021

BACKGROUND: Current guidelines recommend a risk-adjusted treatment strategy for the management of acute pulmonary embolism. This is a particular patient category for whom optimal treatment (anticoagulant treatment, reperfusion strategies, and duration of hospitalisation) is currently unknown. We investigated whether treatment of acute intermediate-risk pulmonary embolism with parenteral anticoagulation for a short period of 72 h, followed by a switch to a direct oral anticoagulant (dabigatran), is effective and safe. METHODS: We did a multinational, multicentre, single-arm, phase 4 trial at 42 hospitals in Austria, Belgium, France, Germany, Italy, Netherlands, Romania, Slovenia, and Spain. …

Malemedicine.medical_specialtyPopulationAdministration OralHemorrhage030204 cardiovascular system & hematologyDrug Administration ScheduleDabigatran03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumans030212 general & internal medicineeducationAgedAged 80 and overeducation.field_of_studyRIGHT-VENTRICULAR DYSFUNCTION VENOUS THROMBOEMBOLISM DABIGATRAN MANAGEMENT WARFARIN HOSPITALIZATION RATIONALE HEPARIN DESIGNHeparinbusiness.industryAnticoagulantsVenous ThromboembolismHematologyGuidelineHeparinMiddle AgedInterim analysismedicine.diseaseThrombosisDabigatran3. Good healthPulmonary embolismClinical trialTreatment OutcomeFemalePulmonary EmbolismbusinessFollow-Up Studiesmedicine.drug
researchProduct

Efficacy of delayed thromboprophylaxis with dabigatran: Pooled analysis

2012

Abstract Introduction Oral thromboprophylaxis with dabigatran etexilate should be initiated as a half dose 1 to 4 h after major orthopaedic surgery. However, a delay in dosing could occur for clinical or logistical reasons. A post hoc analysis was carried out to determine if patients with delayed dosing received adequate anticoagulation. Patients and methods The RE-MODEL™ and RE-NOVATE® trials compared 220 mg and 150 mg dabigatran etexilate with 40 mg enoxaparin. Pooled data for major venous thromboembolism (VTE) and VTE-related mortality (efficacy outcome) and major bleeding events (MBE), MBE/clinically relevant bleeding events, and all bleeding events (safety outcomes) were analysed. Resu…

Malemedicine.medical_specialtyPyridinesAntithrombinsDrug Administration ScheduleDabigatranlaw.inventionDouble-Blind MethodRandomized controlled triallawPost-hoc analysisHumansMedicineOrthopedic ProceduresProspective StudiesDosingEnoxaparinProspective cohort studyAgedbusiness.industryAnticoagulantsVenous ThromboembolismHematologyMiddle Agedmedicine.diseaseDabigatranPulmonary embolismTreatment OutcomeAnesthesiaOrthopedic surgeryBenzimidazolesFemalebusinessVenous thromboembolismmedicine.drugThrombosis Research
researchProduct